Prostate News and Research

RSS

AUA experts urge to focus on urologic health conditions in upcoming year

This new year, make a resolution to improve your health and talk to your doctor about urologic conditions. Although urologic problems may seem embarrassing to talk about, these conditions are more common than you think and a delay in seeking medical attention could cause you unnecessary stress, prolong the problem and even increase your risk for a more serious condition.

30 Dec 2009

TRAP-1 may prevent cancer cell death, current research suggests

Current research suggests that TNF-receptor associated protein-1 (TRAP-1) may prevent cancer cell death. The related report by Leav et al, "Cytoprotective Mitochondrial Chaperone TRAP-1 as a Novel Molecular Target in Localized and Metastatic Prostate Cancer," appears in the January 2010 issue of the American Journal of Pathology.

30 Dec 2009

Phase 3 trial of figitumumab discontinued by Pfizer

Pfizer Inc. announced today the discontinuation of A4021016 (also known as ADVIGO 1016), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) as first-line treatment in patients with advanced non-adenocarcinoma non-small cell lung cancer (NSCLC) due to the study meeting predefined boundaries for early termination.

30 Dec 2009

CGEN-671, a new drug target for multiple epithelial tumors discovered by Compugen

Compugen Ltd. announced today the discovery and experimental validation of CGEN-671, a new drug target for multiple epithelial tumors.

28 Dec 2009

Study suggests routine evaluation does not predict prostate cancer

On the heels of the American Cancer Society's recent controversial response to breast and prostate cancer screenings guidelines, a new study from the Mayo Clinic has emerged analyzing the correlation between prostate-specific antigen (PSA) levels and prostate size. The study discovered that routine annual evaluation of prostate growth does not predict the development of prostate cancer.

24 Dec 2009

Interdisciplinary approach essential for treating men’s' sexual dysfunction

Modern, couple-oriented treatment for male sexual dysfunction takes the psychosocial aspects of sex into account, as well as focussing on the purely physical aspects of the problem.

24 Dec 2009

U.S. Congress approves $1.6 million for AdMeTech Foundation's research program

AdMeTech Foundation, a nonprofit organization, announced today that the U.S. Congress has approved $1.6 million for funding of its groundbreaking research program aimed at developing novel imaging technologies for early prostate cancer detection, which in turn is critical for saving lives and designing customized patient care, including the most effective and the least invasive approach.

23 Dec 2009

New project analyzes genetic sequence and variations of every gene expressed by 1,000 tumors

No two tumors are alike, but analyzing the genetics of cancers from different parts of the body may reveal surprising details useful for treatment and prevention.

22 Dec 2009

Four Latin American cancer patients receive treatment using RapidArc radiotherapy technology

Four cancer patients became the first in Latin America to receive treatment using a fast form of image-guided radiotherapy that potentially enables doctors to improve outcomes while extending modern care to more patients. Doctors at Hope International Centro de Radioterapia of Guatemala are now treating four patients using RapidArc® radiotherapy technology from Varian Medical Systems, one with recurring prostate cancer, one with a nasal cavity tumor, one with rectal cancer, and one with recurring glioblastoma multiforme--an aggressive type of brain tumor.

22 Dec 2009

3rd Annual OneMedForum to highlight therapeutic and diagnostic products for cancers

ProActive Capital Resources Group, a company dedicated to the discovery and creation of value in the small and micro-cap marketplace, is proud to announce client presentations at the 3rd Annual OneMedForum held in San Francisco, January 12-13, 2010. ProActive clients presenting are: Access Pharmaceuticals, ImmunoCellular Therapeutics, DataTrak International, Quantum Immunologics, with Protox Therapeutic's presentation pending.

22 Dec 2009

Genome-wide study of African and African-American ancestry released by scientists

People who identify as African-American may be as little as 1 percent West African or as much as 99 percent, just one finding of a large-scale, genome-wide study of African and African-American ancestry released today.

22 Dec 2009

Novalis Tx radiosurgery platform for modern radiotherapy and radiosurgery unveiled

Slovenian Minister of Health Borut Miklavcic today officially unveiled the nation's first Novalis Tx(TM) radiosurgery platform for modern radiotherapy and radiosurgery at the Oncology Institute of Ljubljana.

22 Dec 2009

CyberKnife Robotic Radiosurgery System brings new hope to patients with inoperable tumors

The CyberKnife Institute at Mercy Hospital, Miami’s first hospital-based CyberKnife® Robotic Radiosurgery System, will bring new hope to patients with inoperable or surgically complex tumors when it opens its doors January of 2010.

22 Dec 2009

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today that they have entered into a global license and collaboration agreement to develop and commercialize OGX-011, as well as an agreement to purchase shares in OncoGenex. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance.

21 Dec 2009

OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries

Isis Pharmaceuticals, Inc. today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation antisense drug co-discovered by Isis and OncoGenex that has completed a successful Phase 2 program in patients with advanced prostate cancer and advanced non-small cell lung cancer.

21 Dec 2009

VA apologizes for faulty prostate-cancer program in Pa. but denies radiation violations

"The Department of Veterans Affairs yesterday apologized repeatedly for a prostate-cancer program that gave incorrect radiation doses to veterans for six years at its main Philadelphia hospital," The Philadelphia Inquirer reports.

18 Dec 2009

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

18 Dec 2009

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the termination of its agreement with sanofi-aventis U.S. ( SNY) dated March 5, 2009 for the development, commercialization and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market, following the Company's announcement last week of the results for its European Phase 3 study for cetrorelix in BPH.

18 Dec 2009

Advanced Medical Diagnostics SA to open 15 Tissue Differentiation Diagnostic Centres

Advanced Medical Diagnostics SA, a privately held company committed to providing innovative computer-aided solutions (HistoScanning™) that improve the diagnostic interpretation of ultrasound scans, today announced a collaboration with the BUND-DER-UROLOGEN for the opening of 15 Tissue Differentiation Diagnostic Centres.

18 Dec 2009

FDA advisory committee votes against approval of Tarceva for lung cancer treatment

Yesterday, an advisory committee to the Food and Drug Administration voted against the approval of Tarceva(R) (erlotinib) as maintenance treatment for advanced lung cancer patients.

18 Dec 2009

Prostate News and Research

AUA experts urge to focus on urologic health conditions in upcoming year

TRAP-1 may prevent cancer cell death, current research suggests

Phase 3 trial of figitumumab discontinued by Pfizer

CGEN-671, a new drug target for multiple epithelial tumors discovered by Compugen

Study suggests routine evaluation does not predict prostate cancer

Interdisciplinary approach essential for treating men’s' sexual dysfunction

U.S. Congress approves $1.6 million for AdMeTech Foundation's research program

New project analyzes genetic sequence and variations of every gene expressed by 1,000 tumors

Four Latin American cancer patients receive treatment using RapidArc radiotherapy technology

3rd Annual OneMedForum to highlight therapeutic and diagnostic products for cancers

Genome-wide study of African and African-American ancestry released by scientists

Novalis Tx radiosurgery platform for modern radiotherapy and radiosurgery unveiled

CyberKnife Robotic Radiosurgery System brings new hope to patients with inoperable tumors

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries

VA apologizes for faulty prostate-cancer program in Pa. but denies radiation violations

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

Advanced Medical Diagnostics SA to open 15 Tissue Differentiation Diagnostic Centres

FDA advisory committee votes against approval of Tarceva for lung cancer treatment

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News